To aid in the validation and interpretive reporting of results from multianalyte diagnostic testing for pheochromocytoma (PHEO), we have developed a desktop personal computer-based laboratory expert system (REPCAT). REPCAT utilizes a commercial database application to run procedures that assess analytical and clinical data relating to patient urine or plasma samples. REPCAT was used to evaluate the raw data from >4000 24-h urine samples submitted to our laboratory for testing for the presence of PHEO. REPCAT performed equivalently to an expert pathologist in assessing the presence and class of PHEO (epinephrine, norepinephrine, or mixed secretor). No false negatives were generated and it assigned a correct interpretation (on the basis of subsequent clinical and biochemical investigation) for each of the primary diagnostic samples from these patients.
With increased automation and productivity in the modern pathology laboratory, the process of validating and interpreting laboratory data can be greatly assisted by the use of some form of computerized decision support system. Expert systems are playing an increasingly important role in this area by enabling the generation of interpretive pathology laboratory reports that can be used in clinical decision support [1, 2] . In many diagnostic investigations, the results from several analytes as well as specific clinical information and knowledge of the therapeutic regimes are required for an accurate assessment of the patient's status. Such an example is the biochemical investigation of pheochromocytoma (PHEO), an uncommon tumor that is easily cured but potentially fatal if diagnosis is not made. 2 Previous investigations have indicated that the diagnosis of PHEO in all patients with the tumor requires a minimum of five analytes to be assessed, both individually and in relation to one another [3, 4] . As a tertiary referral center for PHEO diagnosis, we have accumulated a base of Ͼ8000 "nontumor" patients and some 75 patients with PHEO [3] [4] [5] . These data have been maintained on a Macintosh personal computer by using database applications developed with the database development software products Omnis 5 and Omnis 7 . As well as maintaining the clinical and analytical data, these applications have been used to calculate patient results (and quality control) from raw data derived from a gas chromatography-mass spectrometry (GC-MS) system used in the analysis of urinary and plasma catecholamines and metabolites. More recently we developed an expert system within the database application to interpret individual patient data in relation to reference intervals from the whole nontumor population in the database [6] .
Modern personal computer (PC)-based database systems with lookup file capability provide the necessary framework for developing expert systems within a database, and we took advantage of these to develop REP-CAT. In routine use REPCAT is a fast, easily maintained application that examines 11 analytes and specific data from the sample request for biochemical investigation of PHEO and produces an interpretive report on the results that is equivalent to that from an expert pathologist.
Materials and Methods equipment
REPCAT is an application developed with Omnis 7 (Blyth Software, Foster City, CA/DLA Technology, Sydney Australia), which operates on Macintosh (Apple, Cupertino, CA) computers or IBM-compatibles under Windows (Microsoft, Redmond, WA). In routine laboratory use REPCAT runs on a Macintosh LC575 configured with 8 Mbytes of RAM, which is linked to a laboratory information system (LIS). Development work was carried out on a Macintosh Centris 650 computer. Patient sample records (8300 in the working database) are maintained in an Omnis 7 data file and currently require 6 Mbytes of hard disk drive space.
patient database
The full database contains Ͼ8000 records of patient urine and plasma samples referred to us over the past 10 years for query PHEO. These records contain 65 datafields in the main file and include patient and sample details, clinical comments, and the analytical results for up to 11 analytes. The analytes currently included are the primary catecholamines norepinephrine (NE), epinephrine (EP), dopamine, their ␣-methyl analogs (present if the patient was receiving methyldopa therapy), their primary neuronal metabolites 3,4-dihydroxyphenyl glycol (DHPG) and 3,4-dihydroxyphenylacetic acid (DOPAC), the O-methyl metabolites normetanephrine and metanephrine, and creatinine. Before an analytical run, patient data are imported into the Omnis 7 database from the hospital mainframe LIS. This process was done in two steps by using, first, a menu option on the LIS that exported patient data as a text file from the list of patients requiring to be tested for "query PHEO"; by using the PC in terminal emulation mode, the resulting file was then read into REPCAT with a custom Omnis 7 menu routine. Clinical notes were not recorded in the LIS; this necessitated these to be entered manually into REPCAT for each patient record from the sample request form. After sample analysis, raw data from the GC-MS and HPLC instruments (ASCII files) are read into the patient records in the database over a local area network. Final analyte concentrations are automatically calculated within the REPCAT application.
knowledge base
The knowledge base was derived by first preparing a matrix of analyte concentrations for NE, EP, DHPG, normetanephrine, and metanephrine ranging from grossly high through high, normal, borderline, and low. "High" values for each analyte were defined as those exceeding the upper 95% confidence interval derived from nontumor patients as previously described [5] . On the basis of our experience in assessing samples submitted for query PHEO over a decade, and by analyzing the data from Ͼ70 confirmed PHEO patients in the database, we decided whether an interpretive comment should apply when sample data fitted an analyte/value combination in the matrix. The appropriate comment was written and assigned a short code for indexing. Heuristic knowledge was incorporated into rules where appropriate. As well as primary comments pertaining to analyte concentrations, others were written to apply to rules such as those associated with follow-up samples, or samples derived from previously diagnosed patients, or those originating from an obstetrics or intensive care ward. For each combination included as a rule, the indexed code, its comment, and a parameter description were entered (or, in practice, exported as a text file from a word processor) as three fields into a separate file within the database. This file (the knowledge base) was then used as a lookup file by the REPCAT application that could instantly access the comment applying to a certain sample data combination via the indexed code. Table 1 shows a short selection of the (currently Ͼ300) comments and the associated parameters contained in the lookup rule file. We emphasize that for sample data to meet the conditions for a particular rule associated with certain analyte concentrations in Table 1 (for example, see that for lookup code DH1.90), it must have already passed through more stringent tests for abnormalities in other analytes (see below). A menu procedure was incorporated into REPCAT to facilitate the listing and editing/insertion of rules contained in the knowledge base.
structure of repcat
In Omnis 7, procedures are built from a list of useravailable commands to carry out calculations and (or) logical processing of any record or records within the database. Conditionals can be applied in this way to test the result applying to the current (sample) record against a rule in the knowledge base. "Inferencing" was readily accomplished via Omnis 7 procedures, which we incorporated into the REPCAT application, and extra features found in an inference engine or expert system "shell" [7] were unnecessary. An "expert report" by REPCAT is routinely initiated via a procedure call (procedure number "0," Table 2 ) made at the end of data entry; the task of this procedure is to "sieve" the sample data through a series of procedures to compare the sample results with data from the knowledge base. Table 2 outlines these procedures and their role.
The procedures for rule checking (Table 2) were designed to first test if the sample under consideration was normal in all respects. This was accomplished by a single rule that tested the normality of all analytes, urine volume and creatinine, patient's age, and whether the patient appeared previously in the database. This latter determination was made through a procedure-initiated search of Clinical Chemistry 43, No. 1, 1997 the whole database, made just before rule check, with search criteria based on a concatenated field derived from the patient's surname, first name, and sex. When sample data meet the criteria for complete normality, REPCAT quits the testing procedures and passes appropriate codes to the sample record; in this instance the comment field remains empty. As outlined in Table 2 , if one or more of the parameters relating to a sample are abnormal, the sample data are tested by a further series of procedures built in a hierarchical way so that the sample record accumulates comments and codes for each abnormality found. The series of procedures was designed to allow the data to be tested by the conditional rules (with tests descending from gross abnormalities to minor ones) until there is a correspondence and a rule is "triggered"; the data are then passed to a further procedure to examine for a different abnormality, and so on. Comments derived from each rule triggered are concatenated in the final report to provide a logical explanation for the particular interpretation made. The process of generating an expert report by REPCAT is outlined in Fig. 1 .
While expert comments are written to the sample datafile record whenever data are entered or edited, the expert procedures can also be activated at any time through a pushbutton control. Since searches for prior samples from the current patient are made over the entire database, the time REPCAT takes to process a sample depends on the number of records but is Ͻ1 s, even when Ͼ8000 records are present.
The hierarchical nature of the data test procedures makes the insertion of new rules, when required, a simple task requiring no special computer programming skills; this could be performed by a laboratory scientist in collaboration with a pathologist. For example, referring to Table 1 , if it was decided that a new rule needed to be inserted between consecutive rules N1.10 and N1.12, the lookup file would be entered via the menu and a new record inserted by using, say, code N1.105, the appropriate comment and parameters being entered into their respective fields. After this step is done, it is only necessary to edit the appropriate procedure (in this example it would be procedure number 4 of Table 2 , which points to rules N1.10 to N1.86) by inserting the new conditional test pointing to lookup code N1.105. Similarly, reference intervals (maintained in the database as a single record constants file) can be reset via a menu procedure. How- EPϾXX_UEP & "S_DETAILS" field contains string "icu", "itu", "ICU" or "ITU" Note the patient is from an ITU ward-therefore the increased E is possibly due to E infusion but this needs to be established before the presence of an E-secreting PHEO is excluded.
a NRATIO, NE/DHPG; NORMET, normetanephrine; MET, metanephrine; DA, dopamine. Variables currently have the following values: XX UNE ϭ 4000; X UNE ϭ 2000; UL UNE ϭ 785; BL UNE ϭ 650; XX UEP ϭ 500; X UEP ϭ 200; UL UEP ϭ 150; UL UDH ϭ 980; UL UR ϭ 2.2; X UNM ϭ 10; UL UNM ϭ 5.6; XX UM ϭ 10; X UM ϭ 4; UL UM ϭ 2.1. ever, access could be limited to parts of the system through password protection to prevent unauthorized editing of rules and reference limits.
REPCAT was designed to test both plasma and urine samples submitted for query PHEO, and it provides interpretive reports for both sample types. Because fewer analytes were used for plasma samples (metanephrines not assayed) and creatinine/sample volume data were not relevant, the rules required to test a plasma sample were fewer than those for urine samples (see Table 2 ).
testing The system was initially tested retrospectively on a data set that was used to derive the knowledge base [6] , to which were added rules incorporating the diagnostic utility of the metanephrines. The development data set included some 5000 patient samples queried for PHEO, and 55 of these were diagnosed PHEO. Prospective testing (8000 patient samples) since that time (an additional 40 diagnoses of PHEO) has not revealed any errors in diagnostic logic, nor has it given cause to change the original structure or make any fundamental changes to the knowledge base. No cases of false-negative diagnoses have occurred. Rules were added some 3 years ago to provide for more sophisticated interpretive comments with respect to false-positive data due to drug therapies.
To obtain statistical data on the utility of REPCAT, the system was subjected to analysis by examining the 4321 urine samples (which included 168 samples from 42 confirmed PHEO patients) collected over the 4 years since EP analysis became routine in our laboratory [5] . Data for the metanephrines, which were routinely included by us for PHEO assessment from the beginning of 1990 [4] , were only available for the latter 3000 samples. The complete data for these samples were imported into a separate Omnis datafile upon which the testing was carried out. A short procedure was run to sequentially process each record by REPCAT. The assignments and interpretive comments so produced were then compared with the actual assignments and comments on the original database. Classification of patient groups and subgroups and confirmation of PHEO diagnosis was as previously reported [5] , with patients being classified as non-PHEO if either: (a) initial biochemical testing by GC-MS catecholamine assay was negative and repeat testing was not requested by the referring physician, or (b) initial biochemical screening was positive but repeat GC-MS catecholamine assays and clinical signs were negative. A final diagnosis of PHEO was based on histological confirmation of the presence of PHEO tissue.
Results
Three data fields were considered critical in examining REPCAT's utility and were those cleared of data in the test datafile before running. For all samples run, REPCAT sets a patient classification field (PatClas) to be one of: N (normal), X (unlikely PHEO-a minor abnormality such as increased urine volume, methyldopa present, etc.), Q (possible PHEO-catechol data are abnormal and would usually require further follow-up), or P (confirmed PHEO-only set manually after confirmation or by REP-CAT when the sample is from a previously confirmed PHEO patient). REPCAT sets a second classification field (ProbPheo) to YES if the data are consistent with a probable diagnosis of PHEO. The other field of relevance is the "expert comment" field (RES COMMENT) into which REPCAT places the interpretive result comment.
After REPCAT had run and tested each record (a Fig. 1 . Steps in generating an expert report by REPCAT: 1, patient sample details are imported into the database; clinical notes are entered manually; 2, raw analytical data for each analyte are imported from GC-MS and HPLC instruments to the database. Actual results are calculated by REPCAT (OMNIS 7); 3, REPCAT runs automatically when data entry is complete but can be initiated at any time by a pushbutton control; 4, REPCAT begins by searching the whole patient database for a previous record from the same patient; 5, by referring to the knowledge base the sample data are first checked for complete normalcy by a single rule that tests all analytes, and urine volume and creatinine; 6, any abnormality in the sample data initiates comparison of the sample data with the expert rule base through a hierarchical series of procedures. These procedures allow the data to pass through the conditional rules until there is a correspondence and a rule is triggered and the associated comment and codes are written to the sample data record; 7, a custom-printed report is generated for the current assay. Interpretive comments applying to abnormal sample data are printed along with the analytical results.
process that took ϳ40 min for the 4321 records), 384 samples were classified as Q (abnormal-conditionally requiring follow-up) and, of these, 176 were classified as "probable PHEO." The remaining samples were classified either as normal or as having a nonsignificant abnormality.
On comparison of these data with those for the original records, all positive diagnostic PHEO samples had been correctly assigned a "Q" in the PatClas field and each was also rated as "probable PHEO." Thus, no false negatives were generated by REPCAT. This laboratory is part of a major teaching hospital and a tertiary referral center for PHEO diagnosis. In the 5 years that this expert system, and the diagnostic criteria used by it, have been used, we know of no patient in our database reported as having no biochemical evidence of PHEO who was subsequently diagnosed (including at autopsy) as having a PHEO. It is notable that if the catecholamine data alone were used for diagnostic assessment, four samples (from three patients) would have given false-negative results: In these instances metanephrine data alone were diagnostic. Similarly, if metanephrine data were used alone, three samples from one patient gave a false-negative result: i.e., only catecholamines were positive [4] . REPCAT reports on any and all abnormal data associated with a particular sample and the associated comment is graded according to the degree to which the data diverges from normal. It is up to the clinician to decide if a single specific abnormality (for example, an isolated increase of EP) requires follow-up or is explicable by a cause other than PHEO.
PHEO is heterogeneous in the relative secretion of specific catecholamines, and the biochemical diagnosis of these tumors requires specific assessment of both NE and EP production [4, 5, 8] . In the group of patients with confirmed PHEO, 20 were assessed by REPCAT to be exclusively NE-secreting, 10 were assessed as exclusively EP-secreting, and the remaining 12 were assessed as "mixed" secretors. These assignments by REPCAT were identical to those of an expert pathologist.
The maximum number of false-positive (possible PHEO) samples classified by REPCAT, calculated by subtracting the number of actual positive PHEO samples from the total number of "Q"s, was 208 (5%), and the maximum number of false positives classified probable PHEO was 86 (2%). These results compare favorably with 342 (8%) maximum false-positive results if the number of different false-positive results for each group of analytes (catecholamines and metanephrines) were totalled. The true number of false positives will not be fully determined until follow-up is concluded on 10 of the patients flagged.
Discussion
REPCAT has been in full-time use in our laboratory for 5 years and has proven a fast, highly functional tool, providing the performance of an experienced expert in the domain of investigation of PHEO. It has been 100% sensitive in predicting a diagnosis of PHEO, as well as the PHEO type. It is at least as specific as an expert can be with current knowledge and significantly more specific than if diagnoses were simply based on one class of analyte (i.e., catecholamines or metanephrines). This effectiveness of REPCAT lies in the nature of the domain under consideration; the knowledge is all laboratory based and none is "missing" (not entered).
With regard to the false-positive predictions obtained, a small percentage of patient samples (3.7%) yielding such results has been lost to follow-up, but the majority has been taken to a successful clinical outcome and has returned normal values with further 24-h urine sampling. In many of these cases, however, the initial interpretive report provided by REPCAT was helpful in speeding the follow-up procedure. For example, we have established that patients taking monoamine oxidase inhibitors or tricyclic antidepressant drugs can have a pattern of 24-h urine data not inconsistent with some PHEO types. This profile has been included in one of the rules and, if encountered, results in a comment alerting the clinician to this possible cause of abnormal data. Several such examples of abnormal results from patients who were being medicated with antidepressant drugs occurred in the present series and, being alerted by the report, the clinician was able to respond by taking the patient off the medication before a second urine collection. This would not be expected to happen with a noninterpretive report. Similarly, patients from intensive care or accident emergency wards, who have been subjected to trauma, frequently yield 24-h urine data consistent with PHEO. Here, because the clinical notes field in the patient record is scanned for key words and phrases (e.g., "icu," "itu," "aec," etc.) during processing by REPCAT, it is able to indicate this factor as a possible cause of abnormal data in the report.
Aside from its accuracy and efficiency as an expert system, we believe that by its incorporation into a database application, REPCAT represents a simple approach to practical expert system development in a relatively narrow domain. The method is similar to the concept of a "data dictionary" [9] , which provides a theoretical general basis for systems in which the knowledge base is a maintainable "lookup" file. This approach should be applicable in any domain in which the knowledge base is essentially complete and test results are accurate. If such is the case then even complex diagnostic decision making can be eased because a large number of variables and combinations can be incorporated into the lookup file. All operations are carried out within the database itself.
REPCAT is in routine use in our laboratory and has eased a significant burden in the area of validating and reporting biochemical data for investigation of patients for PHEO. Importantly, it empowers laboratory staff to make informed decisions about the further handling of results and reports. It has proven a valuable educative tool and has resulted in the laboratory staff having a greater appreciation of clinical outcome for the patient.
Clinical Chemistry 43, No. 1, 1997 We believe that REPCAT, or other applications derived from database tools such as Omnis 7, has the potential for use in expert system development in other domains in clinical chemistry.
